Interestingly, OCT1 inhibition may represent a promising way for treatment of hepatic steatosis such as non-alcoholic fatty liver disease, through inhibition of OCT1-mediated thiamine transport and subsequent activation of the energy sensor AMP-activated kinase [27]. Here, POU2F1 is linked to metabolic dysfunction-associated steatotic liver disease.